Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
42 results about "Dopamine reuptake inhibitor" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A dopamine reuptake inhibitor (DRI) is a class of drug which acts as a reuptake inhibitor of the monoamine neurotransmitter dopamine by blocking the action of the dopamine transporter (DAT). Reuptake inhibition is achieved when extracellular dopamine not absorbed by the postsynaptic neuron is blocked from re-entering the presynaptic neuron. This results in increased extracellular concentrations of dopamine and increase in dopaminergic neurotransmission.
Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and / or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.
Owner:SEPACOR INC
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
ActiveUS20090005456A1Improve usabilityOrganic active ingredientsBiocideSynaptic cleftPharmaceutical formulation
Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat / prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
Owner:SUNOVION PHARMA INC
Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
One aspect of the present invention relates to pharmaceutical compositions containing two or more active agents that when taken together can be used to treat, e.g., insomnia and / or depression. The first component of the pharmaceutical composition is a GABA receptor modulating compound. The second component of the pharmaceutical composition is a serotonin reuptake inhibitor, a norepinephrine reuptake inhibitor, a 5-HT2A modulator, or dopamine reuptake inhibitor. In certain embodiments, the pharmaceutical composition comprises eszopiclone. In a preferred embodiment, the pharmaceutical composition comprises eszopiclone and fluoxetine. The present invention also relates to a method of treating a sleep abnormality, treating insomnia, treating depression, augmenting antidepressant therapy, eliciting a dose-sparing effect, reducing depression relapse, improving the efficacy of antidepressant therapy or improving the tolerability of antidepressant therapy, comprising co-administering to a patient in need thereof a GABA-receptor-modulating compound; and a SRI, NRI, 5-HT2A modulator or DRI.
Owner:WOODWARD SPECIALTY LLC
Pharmacological Treatments for Sleep Disorders (Apnoe) With Prostanoid Receptor Antagonists
InactiveUS20080261922A1Preventing and ameliorating sleep-related breathing disorderBiocideNervous disorderNorepinephrine reuptake inhibitorPhosphate
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Tetralone-based monoamine reuptake inhibitors
ActiveUS8053603B2Increase synaptic availabilityImprove usabilityBiocideNervous disorderDiseaseSynaptic cleft
The invention relates to novel tetralone based amines and their use in the treatment of central nervous system (CNS) disorders, such as depression, attention deficit hyperactivity disorder (ADHD) and Parkinson's disease. The invention further relates to pharmaceutical compositions containing the compounds and compositions of the invention as well as methods of inhibiting reuptake of one or more monoamine, such as such as dopamine and norepinephrine, from the synaptic cleft, and methods of modulating one or more monoamine transporter.
Owner:SUNOVION PHARMA INC
Monoamine reuptake inhibitors
The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
Owner:RES TRIANGLE INST
(-)-1-(3,4-Dichlorophenyl)-3-azabicyclo[3.1.0]hexane, compositions thereof, and uses as a dopamine-reuptake inhibitor
InactiveUS20030045567A1Inhibiting dopamine reuptakeInhibiting dopamine uptakePowder deliveryBiocideDiseaseAttention deficits
The present invention relates to (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing a disorder alleviated by inhibiting dopamine reuptake. In one embodiment, the disorder is attention-deficit disorder, depression, obesity, Parkinson's disease, a tic disorder, or an addictive disorder. The (-)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
Owner:DOV PHARMA
Method for treating nervous system disorders and conditions
The present invention is directed to selective dopamine reuptake inhibitors, including (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS), chronic pain, and Shy Drager syndrome.
Owner:WYETH LLC
Medicinal compositions
ActiveUS20060241102A1Shorten the construction periodEffective treatmentBiocideNervous disorderTricyclic antidepressantAmine oxidase inhibitors
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Sydnonimines - specific dopamine reuptake inhibitors and their use in treating dopamine related disorders
InactiveUS20080319030A1Suppressing locomotor activityBiocideSenses disorderDiseaseDopamine transport
Derivatives of Sydnonimine and its analogues, which bind selectively to dopamine transporter (DAT) proteins are useful for treating and delaying the progression of disorders and illnesses that are alleviated by inhibiting dopamine reuptake.
Owner:CHEN HAO +3
Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
ActiveUS9119843B2Attenuate diabetic neurologicalLow extremityBiocideMetabolism disorderAcute hyperglycaemiaNorepinephrine reuptake inhibitor
Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy.
Owner:CAPLIPER LIFE SCI INC
Sydnonimines-specific dopamine reuptake inhibitors and their use in treating dopamine related disorders
Owner:CHEN HAO +3
Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
ActiveUS20120264698A1Effective therapeutic approachBiocideNervous disorderNorepinephrine reuptake inhibitorDisease
Owner:CAPLIPER LIFE SCI INC
Monoamine reuptake inhibitors
The invention provides bupropion analogue compounds capable of inhibiting the reuptake of one or more monoamines. The compounds may selectively bind to one or more monoamine transporters, including those for dopamine, norepinephrine, and serotonin. Such compounds may be used to treat conditions that are responsive to inhibition of the reuptake of monoamines, including addiction, depression, and obesity.
Owner:RES TRIANGLE INST
Method of using dopamine reuptake inhibitors and their analogs for treating diabetes symptoms and delaying or preventing diabetes-associated pathologic conditions
ActiveUS20130131127A1Degradation is usually manifestedLow extremityBiocideMetabolism disorderDopamine reuptake inhibitorHyperglucagonemia
Method of using dopamine reuptake inhibitors, e.g., sydnonimine derivatives, for the management of diabetic symptoms and associated complications or conditions, such as hyperglycemia and diabetic neuropathy.
Owner:CAPLIPER LIFE SCI INC
Synthesis of a serotonin reuptake inhibitor
InactiveUS20140275542A1High chemical purityHigh yield purityOrganic chemistrySerotonin receptor inhibitorsPsychiatry
Owner:DIPHARMA FRANCIS
Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
ActiveUS20140221388A1Effective treatmentNervous disorderAmine active ingredientsSertralineDuloxetine
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
Owner:OTSUKA PHARM CO LTD
Tropane derivatives having dopamine reuptake inhibitor activity for the treatment of ischemic diseases
The present invention relates to the use of tropane derivatives having dopamine reuptake inhibitor activity for the treatment of diseases associated with reduced blood flow to the brain or with instances of a temporary break in blood supply to the brain, such as ischemic diseases.
Owner:SANIONA AS
Method for treating nervous system disorders and conditions
The present invention is directed to selective dopamine reuptake inhibitors, including (−)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, (−)-1-(4-methylphenyl)-3-azabicyclo[3.1.0]hexane, and 1-[2-[bis(4-fluorophenyl)methoxy]ethyl]-4-(3-phenylpropyl)piperazine, and methods of their use for treating certain nervous system disorders and conditions, including, inter alia, vasomotor symptoms (VMS), chronic pain, and Shy Drager syndrome.
Owner:DEECHER DARLENE COLEMAN +1
Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors
ActiveUS8669291B2Improve usabilityBiocideOrganic active ingredientsSynaptic cleftPharmaceutical formulation
Phenyl-substituted cyclohexylamine derivatives and method for their synthesis and characterization are disclosed. Use of these compounds to treat / prevent neurological disorders as well as methods for their synthesis are set forth herein. Exemplary compounds of the invention inhibit reuptake of endogenous monoamines, such as dopamine, serotonin and norepinephrine (e.g., from the synaptic cleft) and modulate one or more monoamine transporter. Pharmaceutical formulations incorporating compounds of the invention are also provided.
Owner:SUNOVION PHARMA INC
Medical compositions of cannabidiol, 5-HT2A receptor antagonist and 5-HT reuptake inhibitor and applications of medical compositions
ActiveCN108143726AReduce dosageReduce or eliminate risk of weight gainNervous disorderHydroxy compound active ingredientsChemical compositionSerotonin 2A Receptors
The invention discloses compositions, and provides a method for preventing and / or treating depression by using the compositions, and applications of the compositions in preparing medicines for preventing and / or treating depression. The compositions contain cannabidiol, a 5-HT2A receptor antagonist, and a 5-HT reuptake inhibitor or medicinal salt thereof, and also can comprise one or more medicinalcarriers or excipients, wherein the use amount of cannabidiol and the use amount of the 5-HT2A receptor antagonist and the 5-HT reuptake inhibitor or the medicinal salt thereof enable the effect of the composition to be superior to that obtained when the medicines with the corresponding dosages are independently used.
Owner:HANYI BIO TECH CO LTD
Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
The pharmaceutical composition of the present invention comprises (1) a carbostyril derivative and (2) a serotonin reuptake inhibitor in a pharmaceutically acceptable carrier. The carbostyril derivative may be aripiprazole or a metabolite thereof, which is a dopamine-serotonin system stabilizer. The serotonin reuptake inhibitor may be fluoxetine, duloxetine, venlafaxine, milnacipran, citalopram, fluvoxamine, paroxetine, sertraline or escitalopram. The pharmaceutical composition of the present invention is useful for treating patients with mood disorders, particularly depression or major depressive disorder.
Owner:OTSUKA PHARM CO LTD
Method of using dopamine reuptake inhibitors and their analogs for treating autoimmune conditions and delaying or preventing autoimmune related pathologic progressions
ActiveUS8691853B2Effective therapeutic approachBiocideNervous disorderAutoimmune conditionAutoimmune disease
Owner:CAPLIPER LIFE SCI INC
Serotonin-norepinephrine reuptake inhibitors (SNRIS) and sigma receptor ligands combinations
InactiveUS20160310500A1Not show side effectNot improveOrganic active ingredientsNervous disorderNorepinephrine reuptake inhibitorAdrenergic
The invention refers to a synergistic combination comprising a Sigma ligand of general formula (I), and a Serotonin-Norepinephrine Reuptake Inhibitor (SNRI), a medicament comprising said active substance combination, and the use of said active substance combination for the manufacture of a medicament, particularly for the prophylaxis and / or treatment of pain.
Owner:LAB DEL DR ESTEVE SA
Monoamine reuptake inhibitors
Owner:RES TRIANGLE INST
Pharmacological treatments for sleep disorders (apnoe) with prostanoid receptor antagonists
This invention is directed to methods for preventing or ameliorating sleep-related breathing disorders. The method comprises administration to a patient in need thereof an effective dose of one or a combination of prostanoid receptor antagonists (eg. ramatroban, ifetroban, diphloretin, phosphate, polyphloretin phosphate, seratrodast, SC19220). The prostanoid receptor antagonist or combination of prostanoid receptor antagonists can be administered in conjunction with one or more serotonin receptor agonists, one or more cannabinoids receptor agonists, one or more serotonin reuptake inhibitors, one or more noradrenalin reuptake inhibitors, a combination of reuptake inhibitors, an inhibitor of prostanoid synthesis, or any combination of the foregoing.
Owner:THE BOARD OF TRUSTEES OF THE UNIV OF ILLINOIS
Pharmaceutical composition
InactiveUS8034820B2Effective treatmentShorten the construction periodBiocideNervous disorderTricyclic antidepressantPurine
The present invention provides pharmaceutical compositions, which are useful for treatment of depression and the like, and which comprises a compound having an adenosine A2A receptor antagonistic activity such as (E)-8-(3,4-dimethoxystyryl)-1,3-diethyl-7-methyl-3,7-dihydro-1H-purine-2,6-dione or a pharmaceutically acceptable salt thereof and an antidepressant drug (for example, a tricyclic antidepressant, a tetracyclic antidepressant, a selective serotonin reuptake inhibitor, a selective noradrenalin reuptake inhibitor, a dopamine reuptake inhibitor, a serotonin-noradrenalin reuptake inhibitor, a monoamine oxidase inhibitor, a 5-HT2 antagonist or the like), and the like.
Owner:KYOWA HAKKO KIRIN CO LTD
Composition of reuptake inhibitor of 5-hydroxytryptamine and noradrenaline and cannabidiol and applications of composition
The invention provides a composition and applications of the composition in preventing and / or treating mental diseases, and in particular relates to a composition of a reuptake inhibitor (SNRI) of 5-hydroxytryptamine and noradrenaline and cannabidiol (CBD) and applications of the composition in preventing and / or treating depression.
Owner:HANYI BIO TECH CO LTD
Monoamine reuptake inhibitors for treatment of CNS disorders
The present invention relates to compounds that are useful exhibit activity as serotonin, norepinephrine and dopamine reuptake inhibitors, and their pharmaceutically acceptable salts, and their use in the treatment of central nervous system and other disorders.
Owner:PFIZER INC
Medicinal composition for treating neurasthenia or somatic form disorders
ActiveCN1850271BOrganic active ingredientsNervous disorderNorepinephrine reuptake inhibitorSertraline
The present invention relates to a method for curing and preventing neurosism or somatic formal disturbance and its medicine composition. Said invention belongs to the field of pharmacy. Said invention provides a medicine composition containing norepinephrine reuptake inhibitor with medicinal dose or its medicinal salt and selective 5-hydroxytryptamine reuptake inhibitor with medicinal dose or its medicinal salt for preventing and curing neurosism or somatic formal disturbance. The norepinephrine reuptake inhibitor is selected from reboxetine, tomoxetine, amfebutamone, nortriptyline, norimipramine, maprotiline and protiline, and the selective 5-hydroxytryptamine reuptake inhibitor is selected from sertraline, citalopram, s-citalopram, fluoroxeline, paroxetine and fluvoxamine.
Owner:SHENZHEN AUSA PHARM CO LTD +2
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com